Bharat Biotech is getting into development and testing of a
vaccine against COVID-19 called CoroFlu as part of an international
collaboration of virologists and vaccine makers.
Background
CoroFlu is a one drop COVID-19 nasal vaccine built on a flu
vaccine “backbone” that has been shown to be safe and well-tolerated in humans,
in Phase I and Phase II clinical trials.
Details
Ø
The company said that the product is part of an
international collaboration of virologists at the University of
Wisconsin–Madison and vaccine companies FluGen along with Bharat Biotech.
Ø
CoroFlu will build on the backbone of FluGen's
flu vaccine candidate known as M2SR. M2SR is a self-limiting version of the
influenza virus that induces an immune response against the flu.
Ø
Researchers will insert gene sequences from
SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, into M2SR
so that the new vaccine will also induce immunity against the coronavirus.
Ø
Under the collaboration agreement, FluGen will
transfer its existing manufacturing processes to Bharat Biotech to enable the
company to scale up production and produce the vaccine for clinical trials.
Ø
Four Phase I and Phase II clinical trials
involving hundreds of subjects have shown the M2SR flu vaccine to be safe and
well tolerated.
Ø
This safety profile, M2SR’s ability to induce a
strong immune response, and the ability of influenza viruses to carry sequences
of other viruses make M2SR an attractive option for rapidly developing CoroFlu
as a safe and effective SARS-CoV-2 vaccine.
Ø
M2SR is a unique form of the flu virus. It lacks
a gene called M2, which restricts the virus to undergoing only a single round
of replication in cells.
Ø
CoroFlu, like M2SR, will be delivered
intranasally. This route of administration mimics the natural route of
infection by coronavirus and influenza and activates several modes of the
immune system.
Ø
Intranasal delivery is more effective at
inducing multiple types of immune responses than the intramuscular shots that
deliver most flu vaccines.
To know more, visit:-➥The Hindu
➥Economic Times
➥The Hindu Businessline
Comments
Post a Comment